Purpose: Prescriptions for hydrocodone immediate-release (IR) combination products have recently decreased, yet they represent the majority of opioid prescriptions dispensed and are commonly abused analgesics among both adults and adolescents. Little data exist to understand the contribution of IR products to the problem of prescription opioid abuse. This study aimed to better understand abuse patterns for hydrocodone IR combination products among adult and adolescent substance abusers.
| INTRODUCTION
Abuse of prescription opioid medications is a significant and pervasive public health problem in the United States affecting the adult and adolescent populations. Of the 21.5 million Americans 12 years or older with a substance use disorder in 2014, 1.9 million involved prescription pain relievers. 1 Further, in 2014, 467 000 adolescents were current nonmedical users of pain relievers, with 168 000 reporting a past year prescription pain reliever use disorder. 1 While the problem is multifaceted, one contributing aspect is overprescribing of these medications and the resulting availability for these products to be diverted for purposes of misuse and abuse. Over a 10-year period from 2000 to 2010, prescriptions of opioid analgesics increased by 104%, with prescribing rates among adolescents and young adults nearly doubling during this time. nationwide (approximately 37%). 4, 5 Hydrocodone is also one of the more commonly abused opioid medications among adults. [6] [7] [8] Further,
hydrocodone IR combination products have also been reported as one of the most common drugs involved in prescription overdose deaths. 9 Recently published data from US poison control centers indicate that for intentional exposures among adolescents specifically, hydrocodone is the most frequently reported misused or abused drug. 10 Several interventions and nationally based efforts have been implemented to lessen the burden of prescription opioid abuse. Strategies to address the prescription opioid abuse epidemic include controls and monitoring of appropriate prescribing practices through implementation of state-wide prescription monitoring programs 11, 12 increased efforts to improve prescriber education related to safe opioid prescribing 13 and more recently, efforts to expand access to and funding for medication-assisted substance abuse treatment services. 14 The US Food and Drug Administration (FDA) has also taken specific steps to improve the safe use of prescription opioids by implementing a class-wide risk evaluation and mitigation strategy for extendedrelease (ER) and long-acting (LA) opioid products. In addition, black box safety warnings for both ER and IR pain medications were issued to highlight the risks of misuse, abuse, overdose, and death due to these products. 15 The FDA also encouraged pharmaceutical companies to develop new drug technologies and abuse-deterrent formulations (ADFs) that address opioid abuse.
In October 2014, the Drug Enforcement Administration (DEA) rescheduled hydrocodone IR combination products from a schedule 3 controlled substance to schedule 2 resulting in certain restrictions in prescribing and dispensing of these opioid medications. 16 While the rescheduling is expected to result in lower abuse and diversion of these products, it is important to understand and characterize their associated patterns of abuse to be able to examine the impact of this change and potential future changes in the opioid landscape. Moreover, hydrocodone IR combination products still remain the most widely prescribed and available opioid products. In addition, although lifetime abuse of IR opioids is at least as prevalent as abuse of ER opioids, nearly all currently marketed opioids with FDA-approved abuse-deterrent product labels are ER products. To further understand abuse of hydrocodone IR combination products, we examined their pattern of abuse among 2 high-risk populations of adults and adolescents assessed for substance abuse treatment problems relative to other opioid compounds including IR and ER products as well as ADF and non-ADF opioid formulations currently on the market.
| METHODS

| Sample description
This study was a cross-sectional design that examined data from adults (ages 18 and older) and adolescents (primarily ages 13 to 18) assessed for substance-abuse problems using 2 data sources from NAVIPPRO®, a public health surveillance system for monitoring patterns and trends in substance abuse including prescription medication use and abuse. 17 We examined prevalence of past 30-day abuse of hydrocodone IR combination products in comparison to other prescription opioids among separate samples of adults who completed an ASI-MV® (Addiction Severity Index Both the ASI-MV and CHAT assessments are structured, self-administered, computerized interviews that measure the severity of a range of problem areas associated with drug and alcohol abuse and are used for clinical assessment and treatment planning on admission to drug and
KEY POINTS
• While the number of prescriptions for hydrocodone IR combination products has recently decreased, these products still represent the majority of opioid prescriptions dispensed in the United States and are commonly abused by both adults and adolescents.
Lifetime abuse of immediate-release opioids is at least as prevalent as abuse of extended-release opioid products, but little data exist to understand their contribution to the problem.
• Postmarket surveillance data were used to examine patterns in abuse prevalence and ROA for hydrocodone IR combination products among 2 highrisk populations of adults and adolescents assessed for substance abuse treatment.
• Abuse prevalence was higher for hydrocodone IR combination products than other opioid categories but was lower than other opioid categories per prescriptions dispensed. Hydrocodone IR combination products had similar abuse prevalence to all ER/LA opioids when considering abuse measured per MME dispensed.
alcohol treatment. [18] [19] [20] where the denominator is equal to the total number of either adult or adolescent assessments). Two additional measures of abuse prevalence were calculated to account for differences in prescription volume across the opioid categories examined including (1) the number of cases of past 30-day abuse for a particular opioid category per 100 000 prescriptions dispensed and (2) the number of cases of past 30-day abuse for a particular opioid compound per 10 000 000 morphine milligram equivalents (MME) dispensed.
Abuse estimates presented as per 10 000 000 MME dispensed were derived using the total weight in milligrams dispensed for each opioid category multiplied by the morphine equivalence factor for each opioid compound. 21 Weights for individual products were summed across all of the available product dosage strengths and across all products included in a specific opioid category. Prescription data for these analyses were obtained from IMS Health using the IDW (Integrated Data Warehouse) pain market prescription database. These data provide national level projected prescription tracking captured at the pharmacy level within the United States and include cash, Medicaid, and third-party transactions.
To examine changes in abuse prevalence and the possible impact of rescheduling of hydrocodone IR combination products in October 2014, an analysis of temporal trend in abuse was conducted using general estimating equation regression models to determine the probabilities of abuse prevalence over time for 2 denominators: (1) abuse per 100 assessments and (2) abuse per 10 000 000 MME. The models estimated period-specific slopes in the rate of abuse for a given opioid category per quarter in the period before and after rescheduling of hydrocodone IR combination products. Models were parameterized where the fixed effects included a categorical indicator variable for period, a time covariate (measured in calendar quarter units), and the interaction of both fixed effects. A log-binomial model was used to estimate changes in linear trends in abuse per 100 assessments across each of the 4 years examined. A log-Poisson model was used to estimate changes in linear trends in abuse per 10 000 000 MME dispensed. The number of assessments and prescription volume, defined as MME, were treated as offsets in the models. 22 Analyses for trend were performed for the adult sample only. Trend analyses were not feasible among the adolescent sample due to small sample size across the period examined.
3 | RESULTS
| Sample demographics
The adult sample consisted of 226 357 assessments from 831 sites in 45 states within the United States during January 2012 through June 2015. Demographically, the adult sample was primarily individuals of younger age (59% between 18 to 34 years) and male (64%).
The majority of adults in the sample were Caucasian race (62.1%) (Table 2) . Overall, 60% of the adult sample were prompted to enter substance abuse treatment via the criminal justice system and nearly 33% reported a chronic pain problem. Approximately 23% reported that they had abused a prescription opioid within the past 30 days. In general, adult prescription opioid abusers within the sample had a similar demographic profile to the total sample with the exception that a lower percentage was prompted to enter treatment by the criminal justice system (36%) and a higher percentage reported a problem with pain (approximately 50% 
| Abuse prevalence of hydrocodone IR combination products
Across the 3.5-year period examined, prevalence of abuse of hydrocodone IR combination products within the adult sample was highest (9.6 per 100 assessments) compared to all other opioid categories examined (range = 3.0 per 100 assessments for all other IR opioids to 8.0 per 100 assessments for oxycodone IR combination products).
For adults, abuse prevalence for hydrocodone IR combination products was nearly twice that of all non-ADF ER/LA opioids (5.2 per 100 assessments) and nearly 3 times that of all ADF ER/LA opioids (3.5 per 100 assessments) (Figure 1 ). Among this sample of adults assessed for substance abuse treatment, the abuse prevalence of hydrocodone IR combination products relative to other prescription opioid categories remained the same annually across the 3.5-year period with abuse of hydrocodone IR combination products remaining higher than the other opioid categories examined including ADF ER/LA opioids and non-ADF ER/LA opioids.
The pattern of past 30-day abuse prevalence for hydrocodone IR combination products and the other opioid categories among adolescent substance abusers was similar to the adult sample where abuse prevalence of both hydrocodone IR combination and oxycodone IR combination products was higher than other opioid categories reviewed ( Figure 2 ). To better understand the role of drug availability (number of prescriptions and amount of opioids dispensed) on abuse across the various opioid categories, prevalence of abuse measured as per 100 000 prescriptions dispensed and measured as per 10 000 000 MME dispensed were included in the analysis. Per prescriptions dispensed, abuse estimates for hydrocodone IR combination products was the lowest of all opioid categories for both adults and adolescents assessed for substance abuse treatment due to hydrocodone IR combination products having the highest volume of prescriptions ( Figures 3A,B) . However, when considering the dosage and potency of the total prescriptions dispensed (MME dispensed) across the 6 opioid categories, abuse prevalence for hydrocodone IR combination products was comparable to ER/LA opioids (among adults 1.16 per 10 000 000 MME dispensed and 1.01 per 10 000 000 MME dispensed, respectively) ( Figures 4A,B ).
| Trend in abuse of hydrocodone IR combination products
Consistent with abuse patterns observed over the total 3.5-year period assessed, hydrocodone IR combination products also had the highest past 30-day abuse prevalence of the opioid categories 
| Route of administration
A variety of ROAs was endorsed by both adults and adolescents who reported past 30-day abuse of hydrocodone IR combination products. the same. Our study also found large differences in the relative ranking of abuse prevalence for hydrocodone IR combination products when measured using the denominator of total prescriptions dispensed versus total MME. Abuse prevalence per total prescriptions dispensed was lower for hydrocodone IR combination products than other opioids examined, a result of the large prescription volume for hydrocodone IR combination products that far exceeds that of the other opioid categories. However, in total MME dispensed, abuse of hydrocodone IR combination products showed prevalence estimates similar to the level observed for all ER/LA opioids combined. Use of these two denominators was intended to provide different perspectives of abuse prevalence by adjusting for the amount of abusable (or "at-risk") product in 2 ways: total prescriptions-by definition, simply adjusts for the number of prescriptions dispensed for a particular opioid product, MME also considers the dosage, number of tablets dispensed, and potency of each opioid, and thus removes some of the distortion in prescription-level prevalence estimates that do not account for these product-specific differences.
A statistically significant upward trend in the slope and prevalence of abuse of hydrocodone IR combination products per 100 assessments and per 10 000 000 MME was observed when comparing the 3 quarters prior to and after rescheduling of these products in October There are notable differences in reported ROAs among prescription opioid analgesic formulations. The preferred ROA most likely reflects the level of attractiveness an abuser perceives for a certain drug, which is itself determined by a myriad of pharmacological, behavioral, and social factors. 24, 25 Furthermore, individual abusers often report using several different routes of abuse. 26, 27 In this study, the ROA pattern among both adults and adolescents who report abuse of hydrocodone IR combination products demonstrate that the predominant ROA for these opioids is the oral route (adults, 90.3%; adolescents, 81.2%) followed by snorting (adults: 23.4%, adolescents:
42.5%). Opioid products including hydrocodone IR combination prod- of exposure or availability of a drug in the community. 26, [29] [30] [31] [32] [33] [34] In the current analysis, abuse prevalence of hydrocodone IR combination products and comparison opioid categories were adjusted for prescribed availability of the products as a proxy for estimating exposure (ie, amount of product potentially available for abuse in the community). In this context, exposure or availability was measured in 2 ways: either per total prescriptions or per total MME dispensed for each product. These values represent abuse based on the total potentially abusable (at-risk) prescriptions circulating in a specified period (ie, cases per 100 000 prescriptions dispensed) or on the dosage and potency level of the opioid evaluated (ie, cases per 10 million MME dispensed). However, given that the number of prescriptions dispensed for hydrocodone IR combination products is much larger than for all other prescription opioids, reliance solely on use of total prescriptions as a denominator in the abuse prevalence estimates may underestimate the true burden of abuse of these products. Prescriptions for hydrocodone IR combination products are typically of shorter duration than the other opioid categories, and these variations across opioid products are not accounted for when using prescription-level use as a denominator in abuse estimates. Furthermore, although a relationship between prescription volume and abuse has been observed, use of total prescriptions as a denominator assumes a linear or proportional relationship between abuse and a product's prescription volume.
A recent analysis of abuse and prescription volume for different opioids suggests that it is possible that there is a point in prescription volume at which the abuse of a product does not proportionally increase with increasing prescriptions. 35 Therefore, it is important to consider empirical evaluation of the current assumptions underlying the relationship between prescription volume and abuse when used as a denominator. These aspects of prescription-based denominators underscore the major differences that can arise in abuse estimates between opioid products solely based on their various prescribing pat- these medications for abuse purposes. Although data from both the adult and adolescent study samples rely on self-report, they are validated clinical instruments [36] [37] [38] [39] that collect data as part of a clinical assessment rather than for pure research purposes. These data may therefore be more accurate as compared to self-report of substance use patterns in general population surveys since data collection occurs as part of patient treatment. Additionally, the data from the ASI-MV and CHAT constitute a uniform and systematic method of data collection over time and across sites with detailed questions that differentiate product-specific abuse and ROA in near real-time. This data collection procedure has been shown to be sensitive to detecting rapid changes in abuse patterns particularly in detecting more recent shifts in prescription opioid abuse after introduction ADFs to the market. 31, 40 In summary, examination of abuse of hydrocodone IR combination products in 2 high-risk populations (adults/adolescents assessed for substance abuse treatment) indicated that abuse of these products impacts a large number of prescription opioid abusers and occurs at a level of severity that represents considerable or extreme abuse behavior. Although proportionally most individuals report oral abuse of hydrocodone IR combination products, snorting also appears to be an ROA for these products that has public health relevance. 
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